Drug
Alovudine clinical trials
Also written 18F-FLT.
- studies test it
- 16
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 4
- Phase 1
- 3
- Phase 2
- 5
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 13
Lederle Laboratories (3) · National Cancer Institute (NCI) (2) · City of Hope Medical Center (1) · M.D. Anderson Cancer Center (1) · University of Texas Southwestern Medical Center (1) · John M. Buatti (1) · University of Washington (1) · Mayo Clinic (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses alovudine is read from its arms, and is right about nine times in ten.
Testing it · 16
- Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and ChemotherapyActive, not recruitingEarly Phase 1City of Hope Medical CenterNCT03422731Written as Fluorothymidine F-18
- 18-FLT PET/MR Imaging to Predict Graft Failure and GVHD in Bone Marrow Transplant PatientsTerminatedEarly Phase 1UNC Lineberger Comprehensive Cancer CenterNCT03546556Written as Fluorothymidine (FLT)
- FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced MalignanciesCompletedPhase 1M.D. Anderson Cancer CenterNCT00880074Written as Fluorothymidine F-18
- Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic AdenocarcinomaCompletedPhase 2University of Texas Southwestern Medical CenterNCT03318497Written as 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT
- A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) TumorsTerminatedPhase 1Dana-Farber Cancer InstituteNCT00633958Written as 18F-FLT
- Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue SarcomaWithdrawnEarly Phase 1OHSU Knight Cancer InstituteNCT03613259Written as Fluorothymidine F-18
- A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or LymphomaTerminatedPhase 1/2AHS Cancer Control AlbertaNCT01065805Written as 18F-FLT
- [F-18] Fluorothymidine PET/CT Imaging for Pelvic CancersCompletedPhase 2John M. BuattiNCT01717391Written as fluorothymidine F 18
- FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast CancerCompletedNot applicableUniversity of WashingtonNCT01928186Written as Fluorothymidine F-18
- 18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing SarcomaCompletedEarly Phase 1Mayo ClinicNCT01825902Written as fluorine F 18 fluorothymidine
- A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLCCompletedPhase 2National Cancer Institute (NCI)NCT00963807Written as FLT
- Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast CancerCompletedPhase 2National Cancer Institute (NCI)NCT00572728Written as 18F-FLT
- 18F-FLT PET for Suspicious Findings on Mammography and Breast UltrasoundStatus unknownNot applicableNational Taiwan University HospitalNCT01713049Written as 18F-FLT
- An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected SubjectsCompletedNot applicableLederle LaboratoriesNCT00002260Written as Alovudine
- An Ascending, Single Oral Dose Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected SubjectsCompletedNot applicableLederle LaboratoriesNCT00002271Written as Alovudine
- A Multi-Center, Open-Label, Ascending, Multiple Oral Dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)CompletedNot applicableLederle LaboratoriesNCT00002254Written as Alovudine
Codes
What other systems call alovudine · ClinicalTrials.gg INT002260
- MeSH (NLM) C002854alovudineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) PG53R0DWDQALOVUDINEConfirmed FDA, NLM, Wikidata
- Wikidata Q4734671alovudineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65226AlovudineOne source FDA
- DrugBank DB06198One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C002854 | alovudine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | PG53R0DWDQ | ALOVUDINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4734671 | alovudine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65226 | Alovudine | One source FDA |
| DrugBank | DB06198 | — | One source Wikidata |
Also registered as alovudine f-18 (UNII 2X1K91UT6N).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.